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ABSTRACT Effective gene therapy for the severe hemo-
globin (Hb) disorders, sickle-cell anemia and thaasmla, wil
require an efficient method to trer, integrate, and express
a globin gene in primary erythroid cells. To evaluate recom-
binant adeno-associated virus (rAAV) for this purpose, we
constructed a rAAV vector Oing a human yglobin gene
(pJM24/vHS432Ay*). Its 4725-nuceotide genome consists of
two 180-bp AAV inverted terminal repeats flanking the core
elements of hypersensitive sites 2, 3, and 4 from the locus
control region of the 3-globin gene cluster, linked to a muta-
tionally marked Aygobin gene (A7*) containing native pro-
moter and RNA processing signals. CD34+ human hematopoi-
etic cells were exposed to rAAV particles at a multiplicity of
infection of 500-1000 and cultured in semisolid medium con-
taining several cytokines. A reverse transcriptase polymerase
chain reaction assay d hed mRNA signals derived from
transduced and endogenous human -globin genes. Twenty to
40% of human erythroid burst-forming unit-derived colonies
expressed the rAAV-transduced A-y*globin gene at levels
4-71% that ofthe endogenous -globin genes. The HbF content
of pooled control colonies was 26%, whereas HbF was 40% of
the total in pooled colonies derived from rAAV tranisduced
progenitors. These data establish that rAAV containing ele-
ments from the locus control region linked to a y'globin gene
are capable oftransferring and expressing that gene in primary
human hematopoletic cells resulting in a substantial increase in
HbF content.
but such vectors have been genetically unstable. Only re-
cently has limited success been reported in achieving signif-
icant globin gene expression using a retroviral vector (13, 14).
Low transduction efficiencies of primate PHSCs (15, 16),
despite up to nearly 100%6 efficiency of gene transfer into
progenitors (17, 18), remain a persistent problem.
Recently, recombinant adeno-associated virus (rAAV)
vectors have emerged as an alternative to retroviral vectors
for the delivery and expression of globin genes (19). High-
level, cell type expression of rAAV transduced globin genes
was shown in hemin-induced K562 cells containing a single
copy of the rAAV genome. Precise LCR regulation of the
rAAV globin gene transcription in these cells was demon-
strated through mutational analysis (20). Using wild-type
AAV and rAAV containing the -3-galactosidase gene, con-
clusive evidence for transduction, integration, and expres-
sion of a proviral AAV genome in primary hematopoietic
cells has been obtained (21). High efficiency transduction of
mouse progenitor cells has been suggested with vectors
containing a gene that confers resistance to neomycin (22).
In the present study, we report transduction of human
hematopoietic progenitor cells with a rAAV vector contain-
ing LCR elements linked to a human Ay* globin gene with its
native promoter, introns, and poly(A) signal. Analysis of
erythroid burst-forming unit (BFU-E)-derived colonies pro-
vided evidence for rAAV-directed 'y-globin gene transcrip-
tion and HbF production in primary erythroid cells.
Human hemoglobin (Hb) disorders such as thalassemia and
sickle-cell disease are a prevalent cause of significant mor-
bidity and mortality worldwide. Therapeutic strategies di-
rected toward genetic modification involve replacement of
the defective gene via allogeneic bone marrow transplanta-
tion or the addition of a functional gene to the defective bone
marrow cells. Characterization ofthe gene defects in patients
with these hemoglobinopathies, as well as extensive charac-
terization of the human 3-globin locus in cultured cells and
transgenic mice, have made gene transfer potentially feasible
(1, 2).
Retroviral vectors have been studied extensively as vehi-
cles for the delivery of globin genes. Successful transduction
of cell lines (3-5), hematopoietic progenitor cells (6, 7), and
pluripotent hematopoietic stem cells (PHSCs) (8-10) has
been achieved using these vectors. Studies in cell lines and
transgenic mice have demonstrated that the locus control
region (LCR), specific sequences distributed over 20 kb
upstream from the P-globin gene cluster, is required for
high-level, integration position-independent expression of
transferred genes (1, 11, 12). The core elements located
within the hypersensitivity sites (HSs) of the LCR have been
incorporated into retroviral vectors linked to a globin gene,
MATERIALS AND METHODS
Construction ofPlasmid JM24/vHS432Ay* and Preparation
of rAAV. The human 3-globin LCR fragments HS4, HS3,
HS2, and the Ay* globin gene (23) were subcloned into
pUC007 (24). A Bgl II/Sal I fiagment of this construct was
subcloned into pUC008 (19), which was then digested with
Nhe I and ligated to the Xba I fragment of pSUB201. Fig. 1A
depicts the structure ofthe HS432Ay* genome and the legend
provides the details of fragments used in its construction.
This plasmid construct, pJM24/vHS432Ay*, was cotrans-
fected with the complementing plasmid, pAAV/ad (25), into
293 cells previously infected with adenovirus type 5 to make
the rAAV, vHS432Ay*. Preparation of cell lysates containing
rAAV, Hirt extracts, and Southern blot analyses are de-
scribed elsewhere (19, 25, 26). All rAAV cell lysates were
concentrated by ultrafiltration using a model 8400 stir cell
apparatus and XM300 membrane (Amicon) prior to heat
inactivation ofadenovirus (560C, 30 min). The final volume of
concentrated cell lysate was =1 ml per 10-cm2 dish of 293
cells used for cotransinfection.
Abbreviations: rAAV, recombinant adeno-associated virus; LCR,
locus control region; RT-PCR, reverse transcriptase polymerase
reaction; BFU-E, erythroid burst-forming unit; HS, hypersensitivity
site; DPP, DNase-protected particle.
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informed consent under a protocol approved by Institute
Review Board of the National Heart, Lung and Blood Insti-
tute. A Ceprate kit (CellPro, Bethell, WA) was used for
CD34+ cell enrichment according to the manufacturer's
protocol. One thousand CD34+ selected cells were exposed
to 500 1.L of rAAV-containing cell lysate (106 particles) in a
total volume of 1000/ul of tissue culture medium (Dulbecco's
modified Eagle medium, 15% fetal calf serum, 50 ng of
interleukin 6 per ml, and 100 ng of stem cell factor per ml).
One transduction (see Fig. 3) was done in tissue culture
medium without growth factors. After an overnight exposure
with gentle rocking at 370C in 5% C02, the cells were
resuspended to 103 cells per ml and plated at 1000 cells per
plate in methylcellulose containing growth factors (10 ng of
granulocyte/macrophage colony-stimulating factor per ml,
10 ng of interleukin 3 per ml, 100 ng of stem cell factor per ml,
and 5 units of erythropoietin per ml). Cells were incubated at
370C in 5% CO2 for 13-19 days prior to analysis ofprogenitor-
derived colonies.
Gene Transfer and Expression. RNA extraction from indi-
vidual colonies was performed by placing each colony (<10
,ul of methylcellulose) in 250 /l of Stat-60 (Tel-Test) accord-
ing to the manufacturer's protocol and maintained at -70'C
until reverse transcriptase PCR (RT-PCR) analysis. RT-PCR
reagents and the thermal-cycler were obtained from Perkin-
Elmer. The reverse transcriptase reactions (42°C/30 min,
A
FIG. 1. Characterization of vHS432Ay*. (A) Schematic of the
rAAV genome and relative position of the primers used to estimate
the particle titer of the cell lysate preparations. The pSUB201-
derived AAV inverted terminal repeats (ITR) flank core regions of
the human f-globin LCR: HS4 (GenBank, 958-1714 bp), HS3
(GenBank, 4281-5179 bp), HS2 (GenBank, 8486-8860 bp), and the
mutationally marked human Ay* gene (23). (B) DPP titer of
vHS432Ay*. Bands represent the 665-bp PCR product spanning the
region defined by the 5' and 3' primers shown above. The PCR
templates were as follows: lane 1, H20 blank; lane 2, mock adeno-
virus-infected cell lysate from cells cotransfected with pAAV/ad and
pJM24/HS432Ay*; lane 3, vHS432Ay* cell lysate extracted with
Stat-60 prior to DNase treatment; lanes 4-6, vHS432Ay* in triplicate;
lanes 7-9, vHS2/A y*/neo (19) cell lysate stock (104 neoR per ml) in
triplicate. A standard curve generated from pJM24/HS432Ay* DNA
of known concentration is shown on the right. (C) Southern blot
analysis of Hirt extracted DNA from cells producing vHS432Ay*
showing dimer (d) and monomer (m) bands. A 1975-bp fragment (Apa
I restriction enzyme fragment of the parent plasmid) containing the
Ay* globin gene was used as a probe.
Assay for Estimation of rAAV Particle Titer. A variation of
previous assays (25) was used to estimate particle number.
Twenty microliters ofrAAV cell lysate was incubated (37°C,
1 hr) with 200 units of DNase (Boehringer Mannheim) in a
final volume of200 ,l (20mM Tris-HCl, pH 8.0/10mM MgCl2
buffer). DNase-protected particle (DPP) viral DNA was
extracted with RNA STAT-60 (Tel-Test, Friendswood, TX)
using the manufacturer's protocol with a final volume of 20
,ul. This technique favors recovery of the low molecular
weight single-stranded DNA genome of the rAAV vector
particles. The polymerase chain reaction (PCR) generated a
665-bp fragment spanning the junction between HS2 and the
Ay* globin gene in HS432Ay* (Fig. 1A). PCR conditions were
as follows: 23 cycles; 95°C/1 min, 58°C/1 min, 72°C/1.5 min;
5' primer, 5'-TCTCAGCCTAGAGTGATGAC; 3' primer,
5'-ATAGTAGCCTTGTCCTCCTC.
Preparation and Transduction ofCD34+ Selected Progenitor
Cells. Human peripheral blood mononuclear cells were ob-
tained by hemapheresis of a patient with Hb SS disease after
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FIG. 2. Analysis of RNA from colonies derived from human
BFU-E transduced with rAAV, vHS432Ay*. (A) Schematic of RT-
PCR assay showing position of the PCR primers. Primer-template
mismatches with the 5' primer that spanned the 6-bp deletion in the
Ay* genes prevented efficient amplification of the endogenous gene
or mRNA sequences; intron-spanning primers (5', 5'-TCGCTTC-
TGGAACGTCTATC; 3', 5'-CACCTTCTTGCCATGTGCCT) dif-
ferentiate Ay* DNA and RNA. Conversely, the 5' primer specific for
the endogenous gene included nucleotides at its 3' end that are part
of the 6-bp deletion in the Ay*-globin gene. (B) Analysis of 5 mock
and 10 vHS432Ay* transduced sickle-cell BFU-E-derived colonies
harvested after 14 days in methylcellulose. Lane B is the minus
template control. Other controls on far right show predicted DNA
(369 bp) and RNA (254 bp) signals. (C) PCR product derived from
10% of the cDNA template using primers specific for the endogenous
y-globin genes. RT-PCR conditions are given in the text.
A
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95°C/5 min) were performed as single or double volume
mixtures, followed by single or matched PCRs (35 cycles;
950C/1 min, 600C/1 min) using the appropriate primers.
RNA-derived PCR mixtures, which included [32P]CTP, were
electrophoresed on 10%6 denaturing polyacrylamide gels and
dried prior to autoradiogram or PhosphorImager analysis.
Comparison of the polyacrylamide gel band intensities was
made using the densitometry function of a Phosphorlmager
(Molecular Dynamics). High-performance liquid chromatog-
raphy HPLC was used for Hb analysis as described (27).
RESULTS
Virus Production. Using the DPP titering assay, the con-
centration of rAAV genome in the cell lysate preparations
was reproducibly estimated (Fig. 1B). DNase treatment was
effective in eliminating amplification of plasmid and genomic
DNA in the cell lysates. Control lysate samples were pre-
pared from 293 cells cotransfected with the pJM24/
vHS432Ay* and pAAV/AD plasmids but not infected with
adenovirus. The PCR amplified signals from these mock cell
lysates were reduced to <1% ofuntreated samples by DNase
treatment (Fig. 1B, lane 2). When the rAAV-containing
lysates were extracted with Stat-60 (the commercial product
contains phenol) prior to DNase treatment, the rAAV particle
genomes were not protected by their capsids from DNase and
therefore the signal was eliminated (Fig. 1B, lane 3). A
standard curve was generated from the band intensities of
PCR products amplified from serial dilutions of plasmid
DNA, and the DPP titer ofvHS432Ayh lysates was estimated
at 1-5 x 106 particles per ml. Stocks ofvHS2/Ay*/neoR (Fig.
1B, lanes 7-9) were estimated to have a titer of 106 physical
particles per ml by the DPP assay; these stocks had an
infectious unit titer of z104 neoR colonies on Detroit 6 cells
in a standard biological titering assay (19). Thus, the DPP
titering assay is consistent with previous data that predict a
particle-to-infectious unit ratio of -100 (25, 28, 29). Southern
blot analysis of Hirt extracted DNA demonstrated the rep-
licated forms ofthe vHS432Ay* genome in 293 cells 24 hr after
transduction (Fig. 1C).
rAAV Transduction of Human BFU-E and At* Gene Ex-
pression in Progenitor-Derived Colonies. The results of the
DPP assay and knowledge that the ratio of physical-to-
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infectious titers of the vector preparations was -100 allowed
us to establish transduction conditions in which the estimated
ratio of infectious particles to target cells was -5-10. Pre-
liminary experiments indicated that vector DNA in medium
or associated with colonies compromised attempts to esti-
mate transduction frequency of clonogenic progenitors by
DNA-based PCR methodologies (data not shown; Fig. 2B).
Asy* DNA signals of variable intensity were present in 80% of
the transduced BFU-E-derived colonies. Because of these
fluctuations, we relied on RT-PCR to evaluate gene transfer
and expression. Using intron-spanning primers, the RT-PCR
assay was designed to distinguish rAAV-derived Ay* RNA
and DNA. The nucleic acids derived from the endogenous
globin genes were not amplified above background levels
with the primers specific for the transduced Ay* globin gene
(Fig. 2B). Distinct A/* RNA-derived signals were found in
20-30% of the colonies derived from erythroid progenitors
exposed to HS432Ay* rAAV (Figs. 2 and 3), while no As
RNA-derived signal was present in a similar number of
nonerythroid colonies (data not shown). In the mRNA pos-
itive BFU-E-derived colonies, comparison of RT-PCR sig-
nals from the rAAV Ay* and endogenous genes (Fig. 2B)
suggested that A?* globin gene expression was around 10%
that of the total -t-globin expression. Hence, our initial data
provided strong evidence for rAAV transduced Ay* gene
transcription in BFU-E exposed to the HS432Ay* vector. A
DNA-derived signal of variable intensity was observed on
analysis in a larger proportion of colonies; in some or all
cases, this signal may represent contamination by viral DNA,
as the physical multiplicity of infection was =1000.
These results have been reproduced in several analyses of
vHS432Ay* transduced peripheral CD34+ progenitor cells; a
second experiment is shown in Fig. 3. In the 19 erythroid
colonies analyzed, equal amounts ofcDNA were taken from
a common RT reaction mixture and used as template for the
PCR amplification ofendogenous and Ay* signals. As shown,
evidence of transcription from the transduced rAAV genome
was present in 7 of 19 colonies analyzed, and the Ay*
RNA-derived signals had intensities from 4% to 71% ofthose
amplified using the same RT reaction mixture with primers
specific for cDNA from the four endogenous t-globin genes.
The range ofrAAV-derived and endogenous signal intensities
in Figs. 2 and 3 supports their use in providing a semiquan-
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FIG. 3. Comparison ofRT-PCR signals for the transduced and endogenous yglobin genes. After completion of the RT reaction, the reaction
mixture for each individual colony was split into equal volumes and used as matched templates for the primer-specific PCRs. (A) Analysis of
19 sickle-cell BFU-E-derived colonies using the assay and Ay*-specific primers shown in Fig. 2. Identification of each signal appears on the far
left. (B) PCR products using the endogenous y-globin specific primers. (C) Percent expression from the rAAV transduced Ay* gene compared
to the yglobin genes in that colony. Each lane contained an equal volume of the PCR mixture. The gels containing endogenous and Ay* generated
signals were then exposed for identical times using a single PhosphorImager screen. Polyacrylamide gel electrophoresis on each sample was
performed twice and signals were averaged. The percentages were calculated by multiplying the ratio of the Ay* RNA-derived signal intensity
and the endogenous yglobin RNA signal intensity by 100.
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titative estimate of the level of rAAV transduced gene
expression. The small amount of RNA available from each
colony precluded other quantitative assays of transcriptional
activity.
Quantitation of Hb Expression in BFU-E-Derived Colonies.
The results of HPLC analysis of the Hbs in colony erythro-
blasts are shown in Fig. 4. The Hb composition of pooled
colonies (>50 erythroid) derived from 1000 mock transduced
progenitors was 26% HbF and 70%o HbS, consistent with the
high level of HbF production in erythroblasts derived from
adult BFU-E when cultured in fetal serum containing medium
(30). The HbF concentration in pooled colonies derived from
an equal number of BFU-E transduced with vHS432A-yI was
40o of the total. Since less than one-half of the colonies were
expressing the vHS432Ay* transferred gene, these data sug-
gested a substantial increase in fetal Hb content in erythro-
blasts derived from transduced progenitors.
DISCUSSION
These experiments were undertaken to evaluate the ability of
rAAV to introduce a globin gene into primitive human
hematopoietic cells and to express the gene in maturing
erythroblasts without selection for cells in which the vector
genome had been successfully introduced. The Ay*-globin
gene linked to the core elements of three of the HSs from the
3-globin gene cluster LCR was expressed at a level that
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FIG. 4. Hb composition of colonies derived from peripheral blood
BFU-E of a patient with sickle-cell anemia. One thousand control
(MOCK) or vHS432A y*-transduced cells were plated in methylcellu-
lose. After 19 days, the colonies (>50 erythroid) from the control or
experimental plates were pooled, washed, and analyzed on cation-
exchange HPLC. Major Hb species are identified by their time of
elution. The integrated areaundereach peak provided an estimate ofthe
Hb composition ofeach pool of colonies. The HbF content was 26% in
the control (MOCK) and 40% in the colonies derived from progenitors
transduced with vHS432Ay*.
ditions established for successful transduction of erythroid
progenitors are potentially applicable to the ex vivo trans-
duction of repopulating hematopoietic stem cells. Our results
suggest that rAAV vectors may be useful for gene therapy of
human Hb disorders.
Our prior work had established that a rAAV vector (vHS2/
Ay*/neoR) containing the Ay*-globin gene linked to the core
region of HS2 and the neoR gene was able to transfer and
express the globin gene in clones of human erythroleukemia
cells selected in G418 (19, 20). The transferred globin gene
was expressed at levels equivalent to that of an endogenous
globin gene. One unrearranged, integrated proviral genome
was present in most drug-selected human erythroleukemia
cell clones, but rearrangement of the integrated vector ge-
nome occurred in a minority of such clones (20). This vector,
however, worked poorly in primary hematopoietic cells,
rearranging if selection was imposed or expressing the trans-
ferred globin gene at low levels in those colonies derived
without drug selection (.L.M., A. Moulten, and A.W.N.,
unpublished observations). By eliminating the drug-
resistance gene and adding the core elements of HS3 and
HS4, we have now derived a vector that appears to be more
stable and to express the transferred globin gene at high levels
in primary erythroid cells. The ability to introduce the vector
genome without selection is a particularly attractive feature
for gene therapy targeted to stem cells.
A larger proportion of colonies was positive for the vector
genome than exhibited expression of the transferred globin
gene when assayed by PCR analysis (Figs. 2 and 3). It is
possible that some progenitors incorporated the vector ge-
nome without expressing it. However, ,results obtained in
transgenic mice suggest that the combination of HS2, HS3,
and HS4 should be sufficient to ensure high-level expression
of a linked globin gene even in single-copy integrants (11, 12).
Rearrangement of the vector genome with loss of regulatory
sequences may have occurred in a proportion of clones (20).
An alternative explanation is that residual vector DNA gave
an artificially high or false signal inDNA from some colonies.
Without appropriate controls and careful quantitative com-
parison of the PCR amplified signals from a transferred and
endogenous gene (21), DNA-based PCR may be unreliable in
estimating rAAV-directed gene transfer efficiencies. The
rAAV viral genome consists of complementing single-
stranded DNAs that are very efficiently amplified by PCR so
that even a low level of contamination may give a false-
positive signal. For this reason, we have relied on the
RT-PCR as a more accurate method of estimating rAAV
transduction efficiency.
rAAV vectors have been shown to transfer and express
exogenous genes in several cell types (31, 32), including
respiratory epithelium (29, 33, 34) and brain cells in vivo
(R.J.S., unpublished observations). As we have shown for
primary hematopoietic cells, efficient transduction requires a
high multiplicity of infection to ensure an excess of biologi-
cally active vector particles over the target cell population.
Stable expression of the gene for the cystic fibrosis trans-
membrane conductance regulator (CFTR) in rabbit respira-
tory epithelium in vivo for >6 months is most consistent with
integration of the rAAV proviral genome (34), and, indeed,
rAAV vector-mediated integration of the CFTR gene in
nonselected cell lines in vitro has been documented by
Southern blot analysis (33). Although we have not formally
demonstrated integration of the vHS432Ay* proviral genome
in erythroid colonies, the high level oftransferred globin gene
expression over 13-19 days in maturing colonies composed
of >1000 cells derived from a single transduced progenitor is
most consistent with proviral integration at an early stage in
colony development. Successful transduction of hematopoi-
etic long-term culture initiating cells by other investigators
using arAAV vector containing the neoR gene with derivation
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of G418-resistant progenitors over 5 weeks in culture also
supports the ability ofrAAV to integrate the proviral genome
in primitive hematopoietic cells (35). Transduction and inte-
gration of a rAAV into murine repopulating cells were
suggested by detection of the proviral sequences in hemato-
poietic tissues by PCR analysis 12 weeks posttransplantation
(36). These data all support the potential of rAAV for stem
cell-targeted gene therapy. However, a formal evaluation of
integration efficiency in cultured cells and demonstration and
expression of the rAAV genome in hematopoietic cells from
long-term transplant recipients will be necessary.
Ofinterest in our experiments is the increased HbF content
in progenitor-derived erythroid colonies following rAAV-
mediated transfer of the Ay*-globin gene. Many factors,
including the source of progenitor cells, the culture medium
and conditions in which they are allowed to differentiate, and
the concerted expression of endogenous and transduced
globin genes, may contribute to the total HbF content in these
cells. Introduction and high-level expression ofan exogenous
y-globin gene into erythroblasts of patients with sickle-cell
anemia are likely to cause unbalanced globin chain synthesis
and a relative excess of non-a chains. Under these condi-
tions, the Hb composition of erythrocytes should reflect the
relative affinity of the (s and ychains for the limiting number
of a chains. The y-globin chain preferentially associates with
a-globin when in competition with the ,3s subunit (37). As
predicted from these observations, rAAV-mediated expres-
sion of the y-globin gene in colony erythroblasts increased
HbF content at the apparent expense of HbS.
The utility of rAAV vectors for gene therapy of Hb
disorders can only be established by testing their ability to
transfer a globin gene linked to LCR elements into repopu-
lating stem cells with subsequent expression in erythroblasts
in vivo. The rhesus autologous bone marrow transplantation
model (16, 38) will be useful for this experiment, as rhesus
hematopoietic progenitors appear to be as efficiently trans-
duced with rAAV as are human cells (21). Although current
methods of vector production yield crude preparation with
relatively low titer, the experiments reported here have
established conditions in which early primate hematopoietic
cells can be efficiently transduced. In the future, improved
packaging systems and methods of vector purification must
be developed if rAAV are to reach clinical application.
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